Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

8.320 -0.230 (-2.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
Intellia Therapeutics's Earnings Outlook
Via Benzinga
The 3 Most Promising Gene Editing Stocks to Buy in 2023
Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in. 
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor has stumbled after a hot start to 2023, but Wood keeps adding to some of her favorite positions. 
Via The Motley Fool
3 Biotech Stocks to Watch After Johnson & Johnson’s Earnings Beat
Discover the latest picks in the biotech industry with our article on 3 biotech stocks to watch after Johnson & Johnson’s earnings beat. 
Via InvestorPlace
3 High-Growth Biotech Stocks Poised for Success in 2023
If you look for growth opportunities wherever you can find them, there are some high-growth biotech stocks that could present an opportunity 
Via InvestorPlace
2 Monster Growth Stocks That Can Double in Value, According to Wall Street
These stocks have some promising growth opportunities, but they also come with a fair amount of risk. 
Via The Motley Fool
Where Intellia Therapeutics Stands With Analysts
Via Benzinga
Analyst Ratings for Intellia Therapeutics
Via Benzinga
Why Is Intellia Therapeutics (NTLA) Stock Up 10% Today?
Huge opportunities also meets unignorable risks 
Via InvestorPlace
Why Intellia Therapeutics Stock Jumped This Week
Intellia Therapeutics landed a historic regulatory nod from the FDA. 
Via The Motley Fool
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
Via Benzinga
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Intellia Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
Via Benzinga
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
3 Beaten-Down Stocks That Could Soar This Year
These stocks could enjoy big rebounds in 2023. 
Via The Motley Fool
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
There are no guarantees that any stock will generate huge returns. But the odds look pretty good for these three growth stocks. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
Via Benzinga
2 Cathie Wood Stocks That Have Tripled Since the 2020 Market Crash
Are these stocks still good buys today? 
Via The Motley Fool
7 Cathie Wood Stocks for Your March Buy List
These top Cathie Wood stocks are just now attempting to pivot higher after a miserable outing for much of 2022. 
Via InvestorPlace
Stock Market Rally Rebounds Despite Rising Yields; Salesforce, Tesla In Focus: Weekly Review
Many leaders flashed buy signals as the indexes rebounded from support. 
Via Investor's Business Daily
Why Is Intellia Therapeutics Stock Trading Higher Today?
Intellia Therapeutics (NASDAQ: NTLA) shares are trading higher on Thursday after the company announced that the FDA cleared its Investigational New Drug application for NTLA-2002 for the treatment of... 
Via Benzinga
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing
The FDA made a bold move in the CRISPR gene-editing realm. 
Via Investor's Business Daily
3 More Mid-Cap Biotechs The Street Sees Doubling
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk. 
Via MarketBeat
Better Buy: Beam Therapeutics or Intellia Therapeutics?
The two clinical-stage gene-editing companies have good long-term prospects. 
Via The Motley Fool
3 Deeply Undervalued Stocks That Could Double Your Money
These cutting-edge biotech stocks hold tremendous upside potential. 
Via The Motley Fool
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.